Ebewe Pharma

Activities: Manufacturing Hi Tech Manufacturing

Trending Articles

  1. Sharp's emissions reduction targets validated by Science Based Targets initiative Sharp, a leader in pharmaceutical packaging, clinical trial supply services and small-scale sterile manufacturing, announces that its near-term and long-term greenhouse gas...
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Wound care at a crossroads: precision manufacturing meets a growing global need The wound care market is undergoing a quiet transformation. Although headlines often focus on breakthrough drugs or cutting-edge wearables, the evolution of wound dressings and...
  3. Gerresheimer achieves leadership status with A- CDP score Sustainability progress earns strong rating for climate disclosure and emissions strategy
  4. Denny Bros celebrates 80 years in business Hugely proud of its Bury St Edmunds heritage, family values and commitment to the environment, Denny Bros has been a local business institution for an impressive 80 years
  5. Qureight analyses of Insilico Medicine’s Phase IIa rentosertib data support preliminary efficacy results and future trial expansion Qureight’s deep-learning image biomarkers and clinical data analytics platform used to analyse enrolled idiopathic pulmonary fibrosis (IPF) patient data, supporting efficacy...

Upcoming event

POWTECH

23-25 September 2025 | Exhibition | Nuremberg, Germany See all

Related Content

Pharmaceutical

Brussels approves acquisition of Ebewe by Novartis

<p>The European Commission has granted competition approval to the takeover of Austria's generic pharmaceuticals company Ebewe SP by Swiss drugmaker Novartis, enabling the Euro 1.3bn deal to go ahead. Although Novartis makes generic medicines through its Sandoz division, the EC concluded that the deal &quot;would not significantly impede effective competition&quot; in Europe. </p>
Media

Novartis to add EBEWE Pharma generic injectables business to Sandoz division

<p>Novartis is to acquire the generic injectables business of Austrian company EBEWE Pharma for Euro 925m (US$1.2bn), providing its Sandoz generic pharmaceuticals division with an opportunity to grow while improving access to many generic oncology medicines.</p>
Subscribe now